- Clinical-stage pharmaceutical company Verseon said it presented its oral anti-coagulant treatment last week at the International Stroke Conference in Honolulu.

The company said it presented pre-clinical efficacy models showing that the product, PROACs, inhibit clot formation as effectively as currently available therapies.

It also presented multiple safety studies showing less bleeding and a sparing of platelet function-features that distinguish PROACs from the currently available NOACs and make them promising therapeutic candidates.

At 9:19am: [LON:VSN] Verseon Corporation Plc share price was 0p at 96p

Story provided by